Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Single-arm, Multicenter Study of the Efficacy and Safety of F520 in Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).

NCT04457830 is registered in ClinicalTrials.gov with Shandong New Time Pharmaceutical Co., LTD as lead sponsor.

NCT NCT04457830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04457830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Single-arm, Multicenter Study of the Efficacy and Safety of F520 in Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).
Lead sponsor
Shandong New Time Pharmaceutical Co., LTD
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2020
Completion date
January 1, 2023
Enrollment
105 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t cell lymphoma